Clinical trial
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients…
NCT00301821 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00301821 |
|---|---|
| Title | Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
| Official title | A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Enrollment | 107 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Apr 1, 2015 |
| First posted | Mar 13, 2006 |
| Last update posted | Oct 9, 2019 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: